Novartis Ag (NVSEF) Amortization (2009 - 2023)

Novartis Ag has disclosed Amortization across 6 years of filings, most recently posting $15.0 million for Q4 2023.

• Amortization for Q4 2023 came in at $15.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was $15.0 million (changed N/A YoY), and the FY2023 annual result was $15.0 million, changed N/A from the prior year.
• Amortization came in at $15.0 million for Q4 2023 at Novartis Ag, down from $98.0 million in the prior quarter.
• In the past five years, Amortization ranged from a high of $218.0 million in Q3 2020 to a low of $15.0 million in Q4 2023.
• The 4-year median for Amortization is $98.0 million (2021), against an average of $114.2 million.
• Across the five-year window, Amortization soared 890.91% in 2020 and slumped 55.05% in 2021, its largest moves.
• Novartis Ag's Amortization stood at $22.0 million in 2019, then jumped by 890.91% to $218.0 million in 2020, then plunged by 55.05% to $98.0 million in 2021, then slumped by 84.69% to $15.0 million in 2023.
• The last three Amortization figures came in at $15.0 million (Q4 2023), $98.0 million (Q4 2021), and $218.0 million (Q4 2020), per Business Quant data.